Invivyd (IVVD) announced positive data from its ongoing Phase 1/2 clinical trial of VYD2311, Invivyd’s novel monoclonal antibody candidate designed to be a superior alternative to COVID-19 ...

Denali Therapeutics (DNLI) announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome in the 24-week treatment period and additional long-term follow-up of its ...

Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical ...

Beam Therapeutics is set to present positive and significant data from the BEACON Phase 1/2 clinical trial of BEAM-101 at a major conference, enhancing visibility and credibility within the ...